局部晚期宫颈癌MRI引导近距离放疗的成本效用分析
该成本效用分析采用马尔可夫模型,从加拿大安大略省公共卫生支付方角度比较MRI引导近距离放疗(MRgBT)与CT引导(CTgBT)及二维(2DBT)近距离放疗。结果显示,在所有患者及低危、高危预后亚组中,MRgBT均提高肿瘤控制、减少副作用且成本更低。敏感性分析支持该结论的稳健性,并识别出治疗癌症复发的成本是影响最大的单一模型参数。
要点
- MRgBT较CTgBT和2DBT在所有患者及低/高危亚组中均更有效且成本更低
- MRgBT通过避免复发治疗和副作用管理的下游成本实现成本节约
- 治疗癌症复发的成本是影响模型结果的最重要单一参数
核心结论
- MRgBT比CTgBT或2DBT更有效且成本更低,因其避免了治疗癌症复发和处理副作用的下游成本。
研究设计与样本
- 构建马尔可夫模型,从加拿大安大略省公共卫生支付方角度评估MRgBT、CTgBT和2DBT的成本效用。
- 效果以质量调整生命年表示,成本以2016年加拿大元表示,报告所有患者及低危和高危亚组的增量成本效果比。
- 进行敏感性分析以评估模型参数不确定性的影响。
主要发现
- MRgBT改善肿瘤控制、减少副作用,且与CTgBT或2DBT相比在所有患者及低危和高危预后亚组中成本均更低。
- 敏感性分析支持结果的稳健性,并识别出治疗癌症复发的成本是影响最大的单一模型参数。
临床怎么用
- 研究结果可帮助医疗服务提供者和政策制定者进行未来基础设施和人力资源规划,以确保对该疾病女性的最佳照护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The standard treatment for locally advanced cervical cancer is external beam radiation therapy and concurrent cisplatin followed by brachytherapy. Traditionally, 2-dimensional brachytherapy (2DBT) or computed tomography guided brachytherapy (CTgBT) has been used, but magnetic resonance guided brachytherapy (MRgBT) improves clinical outcomes and has become the new standard of care. This cost-utility analysis was undertaken to compare MRgBT to CTgBT and 2DBT. METHODS AND MATERIALS: A Markov model was constructed to evaluate the cost-utility from the perspective of the public health care payer in Ontario. Treatment effectiveness, expressed as quality-adjusted life years, and costs, expressed in 2016 Canadian dollars, were evaluated for MRgBT, CTgBT, and 2DBT. Results were reported as incremental cost-effectiveness ratios for all patients and separately for low and high-risk subgroups. Sensitivity analyses were performed to assess the impact of uncertainty in model parameters. RESULTS: MRgBT improved tumor control, reduced side effects, and was less costly compared with either CTgBT or 2DBT for all patients and in low- and high-risk prognostic subgroups separately. Sensitivity analysis supported the robustness of the findings and identified the cost of treating cancer recurrence to be the single most influential model parameter. CONCLUSIONS: MRgBT is more effective and less costly than CTgBT or 2DBT by avoiding downstream costs of treating cancer recurrence and managing side effects. These findings will assist health care providers and policymakers with future infrastructure and human resource planning to ensure optimal care of women with this disease.
引用
- Perdrizet J, D'Souza D, Skliarenko J, et al. A Cost-Utility Analysis of Magnetic Resonance (MR) Guided Brachytherapy Versus Two-Dimensional and Computed Tomography (CT) Guided Brachytherapy for Locally Advanced Cervical Cancer. Int J Radiat Oncol Biol Phys. 2020. PMID: 32169410. doi:10.1016/j.ijrobp.2020.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。